Literature DB >> 9254902

Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974-1993.

C Mettlin1.   

Abstract

BACKGROUND: Advances in medical and public health practice have led to many changes in patterns of prostate cancer care. Data from several studies of prostate cancer by the Commission on Cancer of the American College of Surgeons provide information on the directions, magnitudes, and consequences of these changes.
METHODS: The Commission on Cancer conducts patient care evaluation (PCE) studies based on the voluntary participation of hospital cancer programs and their tumor registries. PCE studies have been conducted repeatedly for prostate cancer covering patients diagnosed as early as 1974 and as recently as 1990. In addition, the National Cancer Data Base of the Commission on Cancer collects data for all forms of cancer from throughout the country. The Commission on Cancer, the American Cancer Society, and the American Urologic Association also has conducted a focused survey of radical prostatectomy outcomes. In aggregate, these multiple studies have accrued 179,366 reports on treatment of prostate cancer patients.
RESULTS: Predominant among practice changes are new techniques of prostate cancer detection and initial evaluation which have led to shifts in disease stage at the time of initial therapy. The proportion of prostate cancer that is localized at the time of detection has increased. Use of radiation therapy and radical prostatectomy has increased as the selection of hormone treatment and no cancer-directed treatment have decreased. Five-year prostate cancer survival has improved for every stage of disease.
CONCLUSIONS: The multiple studies by the Commission on Cancer provide data that are not available from other sources. Continued monitoring of prostate cancer patterns of care may be useful in measuring progress in control of this common disease.

Entities:  

Mesh:

Year:  1997        PMID: 9254902     DOI: 10.1002/(sici)1097-0045(19970801)32:3<221::aid-pros9>3.0.co;2-n

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

Review 1.  Social, prognostic, and therapeutic factors associated with cancer survival: a population-based study in metropolitan Detroit, Michigan.

Authors:  Kevin M Gorey; Eric J Holowaty; Ethan Laukkanen; Isaac N Luginaah
Journal:  J Health Care Poor Underserved       Date:  2003-11

Review 2.  Growth hormone and prostate cancer: guilty by association?

Authors:  A Grimberg; P Cohen
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

3.  Bicalutamide adjuvant to radical prostatectomy.

Authors:  William A See
Journal:  Rev Urol       Date:  2004

4.  Success and failure of single-modality treatment for early prostate cancer.

Authors:  David G McLeod
Journal:  Rev Urol       Date:  2004

5.  Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

Review 6.  Common cancers in the elderly.

Authors:  J Hansen
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

7.  Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Authors:  Richard M Hoffman; Linda C Harlan; Carrie N Klabunde; Frank D Gilliland; Robert A Stephenson; William C Hunt; Arnold L Potosky
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

Review 8.  Multiwalled Carbon Nanotubes as Nanomaterial Tool in the Management of Prostate Cancer: A Possible Nanoformulation Approach.

Authors:  Raja Murugesan; Raman Sureshkumar; Arun Radhakrishnan; Srikanth Jupudi; Manisha Chennu
Journal:  Adv Pharm Bull       Date:  2021-09-29

9.  Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA.

Authors:  Richard M Hoffman; S Noell Stone; David Espey; Arnold L Potosky
Journal:  BMC Cancer       Date:  2005-03-08       Impact factor: 4.430

10.  Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis.

Authors:  Jacqueline E Reilly; Jeffrey D Neighbors; Raymond J Hohl
Journal:  Cancer Biol Ther       Date:  2016-09-13       Impact factor: 4.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.